Fred Lublin, MD

Fred D. Lublin, M.D. is the Saunders Family Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution.

Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA.  He completed his internship in Internal Medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his neurology residency at the New York Hospital, Cornell Medical Center.

As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system.  He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He has since been involved in the development of nearly all of the currently available agents to treat MS. At present, He is involved with several new clinical research protocols on promising agents for treating various aspects of MS.  He was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee.  He was a member of the National MS Society National Board of Directors. He is past Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He was a member of the International Medical & Scientific Board of the Multiple Sclerosis International Federation. Dr. Lublin and his colleagues at the National MS Society have re-defined the clinical course definitions of MS, updated in 2014.  He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin is a member of the international panel that periodically redefines the diagnostic criteria for MS (McDonald Criteria). Dr. Lublin is co-chair of the National Institute of Neurological Diseases and Stroke MS Common Data Element committee and a member of their steering committee. He was a Co-Chief and founding Editor of the journal Multiple Sclerosis and Related Disorders.

Dr. Lublin has published numerous scientific articles and is a member of many professional societies and advisory boards. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He was the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis. Dr. Lublin has received the June Halper Lifetime Achievement Award from the Consortium of Multiple Sclerosis Centers and the Hope Award from the National MS Society.

For more information aboutclinical trials, please call Dr. Lublin's office.

Dr. Lublin offers telemedicine appointments when appropriate. Please call his office to schedule a video visit.

The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.